A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Participants with Advanced Prostate Cancer
Not yet recruitingCTIS2023-509255-14-01
Antev Limited, Antev Nordic ABAdvanced prostate cancer
Target: 44Updated: 2026-01-21